In the February issue of the ARCHIVES, Monson et al1 reported on a small series of cases of patients with primary progressive multiple sclerosis (MS) treated with rituximab. Analyzing the cerebrospinal fluid (CSF) B cell counts in 2 of them, they concluded that rituximab depleted CSF B cells to a lesser degree than peripheral blood B cells. Here we communicate our observations in a patient with relapsing-remitting MS who responded to a combined treatment regimen consisting of rituximab and cyclophosphamide.
Petereit H, Rubbert A. Effective Suppression of Cerebrospinal Fluid B Cells by Rituximab and Cyclophosphamide in Progressive Multiple Sclerosis. Arch Neurol. 2005;62(10):1641–1642. doi:10.1001/archneur.62.10.1641-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: